JP5993010B2 - ピリミド−ピリダジノン化合物及びその使用 - Google Patents

ピリミド−ピリダジノン化合物及びその使用 Download PDF

Info

Publication number
JP5993010B2
JP5993010B2 JP2014527282A JP2014527282A JP5993010B2 JP 5993010 B2 JP5993010 B2 JP 5993010B2 JP 2014527282 A JP2014527282 A JP 2014527282A JP 2014527282 A JP2014527282 A JP 2014527282A JP 5993010 B2 JP5993010 B2 JP 5993010B2
Authority
JP
Japan
Prior art keywords
amino
pyridazin
phenyl
oxo
dihydropyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014527282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524475A5 (enExample
JP2014524475A (ja
Inventor
ベンカテサン アラナパカム
ベンカテサン アラナパカム
アストバリー スミス ロジャー
アストバリー スミス ロジャー
ホサハッリ スブラマニャ
ホサハッリ スブラマニャ
ポトルリ ビジャイ
ポトルリ ビジャイ
クマール パニグラヒ スニル
クマール パニグラヒ スニル
バセッティ ビシュヌ
バセッティ ビシュヌ
クントゥ カルナスレー
クントゥ カルナスレー
Original Assignee
エンドゥ ファーマシューティカルズ，インコーポレイティド
エンドゥ ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンドゥ ファーマシューティカルズ，インコーポレイティド, エンドゥ ファーマシューティカルズ，インコーポレイティド filed Critical エンドゥ ファーマシューティカルズ，インコーポレイティド
Publication of JP2014524475A publication Critical patent/JP2014524475A/ja
Publication of JP2014524475A5 publication Critical patent/JP2014524475A5/ja
Application granted granted Critical
Publication of JP5993010B2 publication Critical patent/JP5993010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2014527282A 2011-08-23 2012-08-23 ピリミド−ピリダジノン化合物及びその使用 Active JP5993010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
US61/526,525 2011-08-23
PCT/US2012/051980 WO2013028818A1 (en) 2011-08-23 2012-08-23 Pyrimido- pyridazinone compounds and use thereof

Publications (3)

Publication Number Publication Date
JP2014524475A JP2014524475A (ja) 2014-09-22
JP2014524475A5 JP2014524475A5 (enExample) 2015-10-15
JP5993010B2 true JP5993010B2 (ja) 2016-09-14

Family

ID=46829884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527282A Active JP5993010B2 (ja) 2011-08-23 2012-08-23 ピリミド−ピリダジノン化合物及びその使用

Country Status (14)

Country Link
US (5) US8729079B2 (enExample)
EP (4) EP4327886A3 (enExample)
JP (1) JP5993010B2 (enExample)
CN (2) CN103974955B (enExample)
BR (1) BR112014003981A2 (enExample)
CA (1) CA2846187A1 (enExample)
DK (2) DK3392252T3 (enExample)
ES (2) ES2690971T3 (enExample)
FI (1) FI3392252T3 (enExample)
HU (1) HUE065564T2 (enExample)
IL (1) IL231082A (enExample)
MX (1) MX361458B (enExample)
PL (1) PL2748166T3 (enExample)
WO (1) WO2013028818A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327886A3 (en) * 2011-08-23 2024-05-22 Libertas Bio, Inc. Pyrimido- pyridazinone compounds and use thereof
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN118105392A (zh) * 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
CN114174298B (zh) * 2019-08-14 2023-08-01 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026B (zh) * 2020-04-30 2024-06-14 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
AU2022421224A1 (en) * 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
JP2025506783A (ja) * 2022-02-23 2025-03-13 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー グサシチニブの固体形態
WO2023192989A2 (en) * 2022-04-01 2023-10-05 Azkarra Therapeutics, Inc. Phthalazinone compounds as parp7 inhibitors
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor
AU2024299978A1 (en) 2023-07-27 2026-03-12 Libertas Bio, Inc. Solid state forms of gusacitinib

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756508A (fr) * 1969-09-24 1971-03-01 Takeda Chemical Industries Ltd Derives de pyrimidopyridazine
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (enExample) 1972-07-29 1974-04-27
JPS50101387A (enExample) * 1974-01-16 1975-08-11
CA1052046A (en) 1974-01-21 1979-04-03 American Cyanamid Company Unsymmetrically substituted 1,4-dioxane-2,5-diones
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
JP2002504550A (ja) 1998-02-25 2002-02-12 ファルマシア・アンド・アップジョン・カンパニー 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体
JP3635238B2 (ja) 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
PL207755B1 (pl) * 2000-09-22 2011-01-31 N V Organon Bicykliczny związek heteroaromatyczny, zawierająca go kompozycja farmaceutyczna i jego zastosowania
WO2002088095A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
CA2577467C (en) 2004-09-30 2013-05-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
WO2006066361A1 (en) 2004-12-24 2006-06-29 The University Of Queensland Method of treatment or prophylaxis
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
EP1869037B1 (en) 2005-03-25 2011-07-27 Tibotec Pharmaceuticals Heterobicylic inhibitors of hvc
US20080194656A1 (en) 2005-04-29 2008-08-14 Monique Jenny Marie Berwaer Benzotriazole Derivatives as Cannabinoid Receptor Antagonists
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
PT2698062E (pt) * 2006-12-28 2015-10-19 Abbvie Inc Inibidores da poli (adp-ribose) polimerase
KR20090130051A (ko) 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
JP2012506386A (ja) 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
MX2012004846A (es) * 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
WO2011079105A1 (en) * 2009-12-23 2011-06-30 Abbott Laboratories Novel thienopyrrole compounds
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
EP4327886A3 (en) * 2011-08-23 2024-05-22 Libertas Bio, Inc. Pyrimido- pyridazinone compounds and use thereof
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
CN118105392A (zh) * 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型

Also Published As

Publication number Publication date
US10183944B2 (en) 2019-01-22
DK2748166T3 (en) 2018-10-29
EP2748166B1 (en) 2018-07-11
EP3392252A1 (en) 2018-10-24
US9382277B2 (en) 2016-07-05
US8729079B2 (en) 2014-05-20
US10647720B2 (en) 2020-05-12
CN108707151B (zh) 2022-06-03
BR112014003981A2 (pt) 2017-03-07
FI3392252T3 (fi) 2024-01-08
EP4327886A2 (en) 2024-02-28
EP3404029A3 (en) 2018-12-12
US20200190095A1 (en) 2020-06-18
EP4327886A3 (en) 2024-05-22
CN103974955A (zh) 2014-08-06
ES2690971T3 (es) 2018-11-23
MX361458B (es) 2018-12-06
DK3392252T3 (da) 2024-01-08
EP3392252B1 (en) 2023-10-04
JP2014524475A (ja) 2014-09-22
IL231082A0 (en) 2014-03-31
WO2013028818A8 (en) 2013-09-19
US20160257691A1 (en) 2016-09-08
PL2748166T3 (pl) 2019-05-31
ES2969977T3 (es) 2024-05-23
MX2014002112A (es) 2014-09-25
US20190092779A1 (en) 2019-03-28
WO2013028818A1 (en) 2013-02-28
US20130053346A1 (en) 2013-02-28
US20140221315A1 (en) 2014-08-07
IL231082A (en) 2016-09-29
EP3404029A2 (en) 2018-11-21
HUE065564T2 (hu) 2024-06-28
EP2748166A1 (en) 2014-07-02
CA2846187A1 (en) 2013-02-28
CN108707151A (zh) 2018-10-26
CN103974955B (zh) 2018-06-19

Similar Documents

Publication Publication Date Title
JP2014524475A (ja) ピリミド−ピリダジノン化合物及びその使用
AU2022206702B2 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
KR102892239B1 (ko) Akt 억제제
US20250122221A1 (en) Six-membered cyclothiazole compound and use thereof
WO2021239133A1 (zh) 作为axl抑制剂的嘧啶类化合物
KR20190114910A (ko) 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
JP2016526545A (ja) スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用
WO2015058661A1 (zh) Bcr-abl激酶抑制剂及其应用
WO2018187294A1 (en) Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
WO2023279938A1 (zh) 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
CN119264065A (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
US8889870B2 (en) Kinase inhibitors
US9820989B2 (en) Method of treating conditions with kinase inhibitors
CN111961035B (zh) 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
HK40107186A (en) Pyrimido- pyridazinone compounds and use thereof
HK40000773A (en) Pyrimido-pyridazinone compounds and methods and use thereof
HK1262920A1 (en) Pyrimido- pyridazinone compounds and use thereof
HK1262920B (en) Pyrimido- pyridazinone compounds and use thereof
WO2025255233A1 (en) Compounds containing fused tricyclic rings as pi3k inhibitors
US20250270217A1 (en) Imidaz0[1,2-a]pyrimidine-5(1 h)-ones having a covalent warhead at the 3-position as wrn inhibitors
CN101374842A (zh) 作为药物剂的氮杂卓并吲哚衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160818

R150 Certificate of patent or registration of utility model

Ref document number: 5993010

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250